Anti-EMR1 antibodies
View Patent ↗The invention provides anti-EGF-like module containing, mucin-like, hormone receptor-like 1 (EMR1) antibodies and methods of using such antibodies to treat EMR1-related diseases.
1. An isolated monoclonal anti-epidermal growth factor-like module containing, mucin-like, hormone receptor-like 1 (EMR1) antibody comprising a V H region and a V L region, wherein the antibody selectively binds to RDIDECRQDPSTCGPNSI (SEQ ID NO:30).
2. The anti-EMR1 antibody of claim 1 , wherein the antibody competes with monoclonal antibody 1E7 for binding to EMR1.
3. The anti-EMR1 antibody of claim 1 , wherein the antibody competes with a monoclonal antibody having the same CDR sequences as monoclonal antibody 1E7 for binding to EMR1.
4. The anti-EMR1 antibody of claim 1 , wherein the antibody comprises:
a V H having a CDR3 amino acid sequence IYYRGFDX 1 (SEQ ID NO:31), wherein X 1 is Q, S, K, or V, a CDR1 amino acid sequence (D/S/N)FG(M/I)H (SEQ ID NO:33), and a CDR2 amino acid sequence VIWSGGST(D/N/Y)YADSVKG (SEQ ID NO:34); and
a V L having a CDR3 amino acid sequence (F/V/T/N)QG(V/S/G/T)H(V/L/P)PLT (SEQ ID NO:35), a CDR1 amino acid sequence (R/K)SSQS(I/L)(V/L)HSNG(N/Y)(N/T)YLE (SEQ ID NO:37) and a CDR2 amino acid sequence R(V/G)SNRAS (SEQ ID NO:38).
5. The anti-EMR1 antibody of claim 4 , wherein the V H has a V-segment sequence of a V H region of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, or SEQ ID NO:11; and the V L has a V-segment sequence of a V L region of SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, or SEQ ID NO:22.
6. The antibody of claim 4 , wherein the antibody has a V H region sequence of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, or SEQ ID NO:11; and a V L region sequence of SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, or SEQ ID NO:22.
7. The anti-EMR1 antibody of claim 1 , wherein the antibody has:
(a) the heavy chain CDR1, CDR2, and CDR3 of SEQ ID NO:8, SEQ ID NO:4, SEQ ID NO:9, or SEQ ID NO:11, and the light chain CDR1, CDR2, and CDR3 of SEQ ID NO:17;
(b) the heavy chain CDR1, CDR2, and CDR3 of SEQ ID NO:9 and the light chain CDR1, CDR2, and CDR3 of SEQ ID NO:18;
(c) the heavy chain CDR1, CDR2, and CDR3 of SEQ ID NO:6 and the light chain CDR1, CDR2, and CDR3 SEQ ID NO:15;
(d) the heavy CDR1, CDR2, and CDR3 of SEQ ID NO:7 and the light chain CDR1, CDR2, and CDR3 of SEQ ID NO:16;
(e) the heavy chain CDR1, CDR2, and CDR3 of SEQ ID NO:11 and the light chain CDR1, CDR2, and CDR3 of SEQ ID NO:21 or SEQ ID NO:22; or
(f) the heavy chain CDR1, CDR2, and CDR3 of SEQ ID NO:9 and the light chain CDR1, CDR2, and CDR3 of SEQ ID NO:21.
8. An antibody preparation comprising an anti-EMR1 antibody of claim 1 , wherein the antibody has a heavy chain constant region that is hypofucosylated or afucosylated.
9. A pharmaceutical composition comprising a physiologically acceptable carrier and an antibody of claim 1 .
10. An anti-EMR1 antibody that has a heavy chain and a light chain, wherein the antibody has:
a heavy chain variable region that has a V H region sequence of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, or SEQ ID NO:11; and a light chain variable region that has a V L region sequence of SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, or SEQ ID NO:22.